Literature DB >> 2844673

Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice.

A J Winter1, G E Rowe, J R Duncan, M J Eis, J Widom, B Ganem, B Morein.   

Abstract

A single vaccination of mice with a complex of porin and smooth lipopolysaccharide (porin-S-LPS) extracted from virulent Brucella abortus 2308 provided significant protection (P less than 0.01 to P less than 0.001) against challenge with the same strain, equivalent to that achieved by vaccination with living attenuated B. abortus 19. The porin-S-LPS vaccine given without adjuvant or in several adjuvants (trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes) provided equivalent protection. In contrast, one vaccination with porin complexed with rough LPS (porin-R-LPS) from a rough mutant of strain 2308 provided no protection with any adjuvant tested. In one experiment, two inoculations with the porin-R-LPS resulted in a low level of protection, probably owing to priming of the animals for production of O-polysaccharide-specific antibodies. However, one vaccination with rough-strain porin covalently bound to purified O polysaccharide conferred protection equal to that obtained with natural complexes of porin-S-LPS or with living strain 19. A synthetic vaccine containing long chains of O polysaccharide was more effective than one prepared with short chains. Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative association between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice. These results provide additional evidence that the O polysaccharide will constitute an essential component of an effective subcellular vaccine against B. abortus and that O-polysaccharide-specific antibodies play an important role in protective immunity in brucellosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844673      PMCID: PMC259654          DOI: 10.1128/iai.56.11.2808-2817.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Resistance against a subcutaneous Brucella challenge of mice immunized with living or dead Brucella or by transfer of immune serum.

Authors:  P Pardon
Journal:  Ann Immunol (Paris)       Date:  1977 Nov-Dec

2.  Polyadenylic acid-polyuridylic acid (poly A : U) and experimental murine brucellosis. II. Macrophages as target cells of poly A : U in experimental brucellosis.

Authors:  E D Madraso; C Cheers
Journal:  Immunology       Date:  1978-07       Impact factor: 7.397

Review 3.  Synthetic immunostimulants derived from the bacterial cell wall.

Authors:  E Lederer
Journal:  J Med Chem       Date:  1980-08       Impact factor: 7.446

4.  The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance.

Authors:  R Hunter; F Strickland; F Kézdy
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

5.  Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice.

Authors:  N Bosseray
Journal:  Br J Exp Pathol       Date:  1978-08

6.  Purification and characterization of smooth and rough lipopolysaccharides from Brucella abortus.

Authors:  E Moreno; M W Pitt; L M Jones; G G Schurig; D T Berman
Journal:  J Bacteriol       Date:  1979-05       Impact factor: 3.490

7.  Isolation and characterization of toxic fractions from Brucella abortus.

Authors:  L B Tabatabai; B L Deyoe; A E Ritchie
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum.

Authors:  S Bascoul; A Cannat; M F Huguet; A Serre
Journal:  Immunology       Date:  1978-08       Impact factor: 7.397

9.  Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium.

Authors:  S B Svenson; M Nurminen; A A Lindberg
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

10.  Immunization with major outer membrane proteins in experimental salmonellosis of mice.

Authors:  N Kuusi; M Nurminen; H Saxen; M Valtonen; P H Mäkelä
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more
  26 in total

1.  Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Authors:  L E Lindler; T L Hadfield; B D Tall; N J Snellings; F A Rubin; L L Van De Verg; D Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum.

Authors:  L N Araya; A J Winter
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

3.  Immunological response to the Brucella abortus GroEL homolog.

Authors:  J Lin; L G Adams; T A Ficht
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Brucella abortus cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells.

Authors:  G Briones; N Iñón de Iannino; M Roset; A Vigliocco; P S Paulo; R A Ugalde
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Immune responses of elk to initial and booster vaccinations with Brucella abortus strain RB51 or 19.

Authors:  S C Olsen; S J Fach; M V Palmer; R E Sacco; W C Stoffregen; W R Waters
Journal:  Clin Vaccine Immunol       Date:  2006-10

6.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Cloning and nucleotide sequence of the gene coding for the major 25-kilodalton outer membrane protein of Brucella abortus.

Authors:  P de Wergifosse; P Lintermans; J N Limet; A Cloeckaert
Journal:  J Bacteriol       Date:  1995-04       Impact factor: 3.490

8.  Antibody response to Brucella ovis outer membrane proteins in ovine brucellosis.

Authors:  J I Riezu-Boj; I Moriyón; J M Blasco; C Gamazo; R Díaz
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

9.  O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry.

Authors:  A Cloeckaert; V Weynants; J Godfroid; J M Verger; M Grayon; M S Zygmunt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

10.  Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.

Authors:  M P Jiménez de Bagüés; P H Elzer; S M Jones; J M Blasco; F M Enright; G G Schurig; A J Winter
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.